Base de dados : MEDLINE
Pesquisa : D04.210.500.155.580.130.500 [Categoria DeCS]
Referências encontradas : 4990 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 499 ir para página                         

  1 / 4990 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28398365
[Au] Autor:Cosmi F; Tarquini B; Mariottoni B; Cosmi D
[Ad] Endereço:Dipartimento Cardiovascolare e Neurologico, Cardiologia Valdichiana, USL 8, Arezzo.
[Ti] Título:[Digitalis, a drug to be scrapped?]
[Ti] Título:La digitale: un farmaco da rottamare?.
[So] Source:G Ital Cardiol (Rome);18(2):121-128, 2017 Feb.
[Is] ISSN:1827-6806
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:We performed a comprehensive review of the scientific literature on the use of digoxin in heart failure and atrial fibrillation. In congestive heart failure (CHF) there is only one randomized trial with a statistical sample sufficiently large. In this trial (DIG trial), which enrolled patients with systolic left ventricular dysfunction in sinus rhythm, digoxin had a neutral action on mortality and modestly reduced the overall need of hospitalization. The study was conducted in the pre-beta-blocker era and, therefore, it has a doubtful application to the current clinical context. There are no randomized trials on atrial fibrillation, either with or without heart failure. Several observational and retrospective studies and meta-analysis have shown an association between the use of digoxin and increased mortality about 20%. Both in the European and American guidelines, even in class I recommendations, evidence is not supported by randomized or observational trials, but just by experts' opinions. Digoxin use in CHF and atrial fibrillation is related to the physician's clinical judgment, based more on consolidated custom that on established scientific evidence. In our opinion, this therapy should be withdrawn until new randomized controlled trials will provide evidence of its efficacy. Two trials have been planned to this aim. Also the issue of toxicity threshold is still unresolved; digoxinemia values should be <1 ng/ml if digoxin is used, to avoid overdosing and toxicity with increased mortality.
[Mh] Termos MeSH primário: Fibrilação Atrial/tratamento farmacológico
Cardiotônicos/uso terapêutico
Glicosídeos Digitálicos/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Guias de Prática Clínica como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Digitalis Glycosides)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1714/2663.27297


  2 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28242045
[Au] Autor:Okumura Y; Sakata N; Takahashi K; Nishi D; Tachimori H
[Ad] Endereço:Research Department, Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan. Electronic address: yokumura@blue.zero.jp.
[Ti] Título:Epidemiology of overdose episodes from the period prior to hospitalization for drug poisoning until discharge in Japan: An exploratory descriptive study using a nationwide claims database.
[So] Source:J Epidemiol;27(8):373-380, 2017 Aug.
[Is] ISSN:1349-9092
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Little is known about the nationwide epidemiology of the annual rate, causative substance, and clinical course of overdose-related admission. We aimed to describe the epidemiology of overdose episodes from the period prior to hospitalization for drug poisoning until discharge to home. METHODS: We assessed all cases of admission due to overdose (21,663 episodes) in Japan from October 2012 through September 2013 using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. RESULTS: The annual rate of overdose admission was 17.0 per 100,000 population. Women exhibited two peaks in admission rates at 19-34 years (40.9 per 100,000) and ≥75 years (27.8 per 100,000). Men exhibited one peak in the admission rate at ≥75 years (23.7 per 100,000). Within 90 days prior to overdose, ≥60% and ≥9% of patients aged 19-49 years received a prescription for benzodiazepines and barbiturates, respectively. In addition, 59% of patients aged ≥75 years received a prescription for benzodiazepines prior to overdose, 47% had a history of congestive heart failure, and 24% had a diagnosis of poisoning by cardiovascular drugs. The proportion of patients with recent psychiatric treatments decreased with age (65.1% in those aged 35-49 years and 13.9% in those aged ≥75 years). CONCLUSIONS: The findings emphasize the need for overdose prevention programs that focus on psychiatric patients aged 19-49 years who are prescribed benzodiazepines or barbiturates and on non-psychiatric patients aged ≥75 years who are prescribed benzodiazepines or digitalis.
[Mh] Termos MeSH primário: Overdose de Drogas/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Barbitúricos/envenenamento
Barbitúricos/uso terapêutico
Benzodiazepinas/envenenamento
Benzodiazepinas/uso terapêutico
Bases de Dados Factuais
Glicosídeos Digitálicos/envenenamento
Glicosídeos Digitálicos/uso terapêutico
Feminino
Hospitalização
Seres Humanos
Revisão da Utilização de Seguros
Seguro Saúde
Japão/epidemiologia
Masculino
Transtornos Mentais/tratamento farmacológico
Meia-Idade
Alta do Paciente
Envenenamento/terapia
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Barbiturates); 0 (Digitalis Glycosides); 12794-10-4 (Benzodiazepines)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170301
[St] Status:MEDLINE


  3 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27863364
[Au] Autor:Frommeyer G; Puckhaber D; Ellermann C; Dechering DG; Kochhäuser S; Leitz P; Reinke F; Eckardt L
[Ad] Endereço:Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany. Electronic address: gerrit.frommeyer@ukmuenster.de.
[Ti] Título:Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone.
[So] Source:Int J Cardiol;228:74-79, 2017 Feb 01.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A post hoc analysis of the PALLAS trial suggested possible interactions of dronedarone and digitalis glycosides. The aim of the present study was to compare the effects dronedarone or amiodarone in combination with digitalis glycosides. METHODS AND RESULTS: Eleven female rabbits underwent chronic oral treatment with amiodarone (50mg/kg/d for 6weeks). Ten rabbits were treated with dronedarone (50mg/kg/d for 6weeks). Ten rabbits were used as controls. Hearts were isolated and Langendorff-perfused. Monophasic action potentials and ECG showed a moderate prolongation of QT interval and action potential duration (APD). Both drugs also increased effective refractory period. Additional application of ouabain (0.2µM) resulted in a significant decrease of QT interval, APD, and ERP in all groups. Ventricular arrhythmias were induced by programmed ventricular stimulation and aggressive burst stimulation. Reproducible occurrence was defined as occurrence of at least 3 episodes. Under baseline conditions in control hearts, ventricular fibrillation (VF) was inducible in 1 of 10 hearts (7 episodes). After the application of 0.2µM ouabain, 4 of 10 control hearts were inducible (24 episodes). One of 10 dronedarone-pretreated hearts (3 episodes) and 2 of 11 amiodarone-pretreated hearts (6 episodes) showed VF before ouabain infusion. After the application of 0.2µM ouabain, 7 of 10 dronedarone-pretreated hearts were inducible (73 episodes). By contrast, only 4 of 11 amiodarone-pretreated hearts (13 episodes) showed VF. CONCLUSION: In the present study, additional treatment with ouabain resulted in an increased ventricular vulnerability in al study groups. Of note, chronically dronedarone-pretreated hearts were significantly more vulnerable than amiodarone-pretreated hearts.
[Mh] Termos MeSH primário: Amiodarona/análogos & derivados
Amiodarona/farmacologia
Glicosídeos Digitálicos/farmacologia
Sistema de Condução Cardíaco/efeitos dos fármacos
Fibrilação Ventricular
[Mh] Termos MeSH secundário: Potenciais de Ação/efeitos dos fármacos
Animais
Antiarrítmicos/farmacologia
Modelos Animais de Doenças
Interações Medicamentosas
Eletrocardiografia/métodos
Coelhos
Fibrilação Ventricular/diagnóstico
Fibrilação Ventricular/tratamento farmacológico
Fibrilação Ventricular/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 0 (Digitalis Glycosides); JQZ1L091Y2 (dronedarone); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE


  4 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27135824
[Au] Autor:Liu R; Chang Q; Liu A
[Ad] Endereço:Renmin Street, Jinzhou, Liaoning Province, 121001, China. Electronic address: liurenguanglaoshi@126.com.
[Ti] Título:Permanent atrial fibrillation: Special electrocardiogram in hyperkalemia.
[So] Source:Int J Cardiol;215:519-20, 2016 Jul 15.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Fibrilação Atrial/sangue
Fibrilação Atrial/fisiopatologia
Hiperpotassemia/diagnóstico
Hiperpotassemia/fisiopatologia
[Mh] Termos MeSH secundário: Fibrilação Atrial/tratamento farmacológico
Glicosídeos Digitálicos/administração & dosagem
Glicosídeos Digitálicos/efeitos adversos
Gerenciamento Clínico
Diuréticos/administração & dosagem
Diuréticos/efeitos adversos
Quimioterapia Combinada
Eletrocardiografia/métodos
Feminino
Seres Humanos
Hiperpotassemia/sangue
Meia-Idade
Potássio/administração & dosagem
Potássio/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; EDITORIAL
[Nm] Nome de substância:
0 (Digitalis Glycosides); 0 (Diuretics); RWP5GA015D (Potassium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160503
[St] Status:MEDLINE


  5 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27098360
[Au] Autor:Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
[Ad] Endereço:Laboratory of Cardiovascular Clinical Pharmacology, IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
[Ti] Título:Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
[So] Source:Eur J Heart Fail;18(7):840-8, 2016 Jul.
[Is] ISSN:1879-0844
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently co-exist, and each is a major public health issue. In a large cohort of hospitalized HF patients, we evaluated: (i) the impact of COPD on clinical outcomes; (ii) whether outcomes and treatments changed from 2002 to 2009; and (iii) the relationship between outcomes and treatments focusing on beta-blockers (BBs) and bronchodilators (BDs). METHODS AND RESULTS: From linkable Lombardy administrative health databases, we selected individuals with a discharge diagnosis of HF with or without concomitant COPD (HF yesCOPD and HF noCOPD) in 2002 and 2009. Patients were followed up for 4 years. Outcomes were total mortality, first readmission for HF, and their combination. Unadjusted and adjusted Cox proportional models and competing risk analyses were used. We identified 11 274 patients with HF noCOPD and 2837 with HF yesCOPD. HF yesCOPD patients in 2002 and 2009 had a 20% higher risk of the outcomes. From 2002 to 2009, BB and BD prescriptions increased significantly. In HF noCOPD patients, risks for mortality [adjusted hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.86-0.97], first HF readmission (HR 0.79, 95% CI 0.74-0.85), and the combined endpoint (HR 0.88, 95% CI 0.84-0.92) declined (all P < 0.003) while in HF yesCOPD only the risk for first HF readmission dropped (HR 0.86, 95% CI 0.76-0.97; P = 0.018). BBs were associated with significantly lower mortality in both groups, but with a higher risk for first HF readmission in HF noCOPD. Outcomes did not significantly differ in HF yesCOPD treated or not with BDs. CONCLUSIONS: The prognosis of patients hospitalized for HF, either with or without COPD, seemed to improve between 2002 and 2009, with possibly better survival of those on BBs. Because of residual confounding in observational studies, a randomized controlled trial should be considered to confirm these results.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/uso terapêutico
Broncodilatadores/uso terapêutico
Insuficiência Cardíaca/terapia
Mortalidade
Readmissão do Paciente/estatística & dados numéricos
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Agonistas Adrenérgicos beta
Idoso
Idoso de 80 Anos ou mais
Antagonistas de Receptores de Angiotensina/uso terapêutico
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Antiarrítmicos/uso terapêutico
Anticoagulantes/uso terapêutico
Bloqueadores dos Canais de Cálcio/uso terapêutico
Terapia de Ressincronização Cardíaca
Antagonistas Colinérgicos
Estudos de Coortes
Glicosídeos Digitálicos
Diuréticos/uso terapêutico
Feminino
Insuficiência Cardíaca/complicações
Hospitalização
Seres Humanos
Hipolipemiantes
Armazenamento e Recuperação da Informação
Masculino
Meia-Idade
Antagonistas de Receptores de Mineralocorticoides/uso terapêutico
Análise Multivariada
Nitratos
Inibidores da Agregação de Plaquetas
Modelos de Riscos Proporcionais
Doença Pulmonar Obstrutiva Crônica/complicações
Resultado do Tratamento
Xantinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Adrenergic beta-Agonists); 0 (Adrenergic beta-Antagonists); 0 (Angiotensin Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Anti-Arrhythmia Agents); 0 (Anticoagulants); 0 (Bronchodilator Agents); 0 (Calcium Channel Blockers); 0 (Cholinergic Antagonists); 0 (Digitalis Glycosides); 0 (Diuretics); 0 (Hypolipidemic Agents); 0 (Mineralocorticoid Receptor Antagonists); 0 (Nitrates); 0 (Platelet Aggregation Inhibitors); 0 (Xanthines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160422
[St] Status:MEDLINE
[do] DOI:10.1002/ejhf.519


  6 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26786040
[Au] Autor:Fins JJ
[Ti] Título:What's Wrong with Evidence-Based Medicine?
[So] Source:Hastings Cent Rep;46(1):insidebackcover, 2016 Jan-Feb.
[Is] ISSN:0093-0334
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Medicine in the last decades of the twentieth century was ripe for a data sweep that would bring systematic analysis to treatment strategies that seemingly had stood the test of time but were actually unvalidated. Coalescing under the banner of evidence-based medicine, this process has helped to standardize care, minimize error, and promote patient safety. But with this advancement, something of the art of medicine has been lost.
[Mh] Termos MeSH primário: Lista de Checagem
Protocolos Clínicos
Medicina Baseada em Evidências
Narração
Satisfação do Paciente
[Mh] Termos MeSH secundário: Fibrilação Atrial/tratamento farmacológico
Certificação
Lista de Checagem/normas
Protocolos Clínicos/normas
Glicosídeos Digitálicos/uso terapêutico
Medicina Baseada em Evidências/normas
Seres Humanos
Medicina Interna/normas
Erros Médicos/prevenção & controle
Assistência ao Paciente/normas
Segurança do Paciente/normas
Padrões de Prática Médica/normas
Padrões de Prática Médica/tendências
Conselhos de Especialidade Profissional
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Digitalis Glycosides)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:160120
[Lr] Data última revisão:
160120
[Sb] Subgrupo de revista:E; IM
[Da] Data de entrada para processamento:160121
[St] Status:MEDLINE
[do] DOI:10.1002/hast.534


  7 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25259953
[Au] Autor:Fürstenwerth H
[Ti] Título:Why Whip the Starving Horse When There Are Oats for the Starving Myocardium?
[So] Source:Am J Ther;23(5):e1182-7, 2016 Sep-Oct.
[Is] ISSN:1536-3686
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Digoxin is the oldest drug for treatment of heart failure still in clinical use. Despite over 200 years of clinical experience with this drug, the optimal serum concentration required for both efficacy and safety remains unknown. It has been suggested that low doses have more favorable effects than higher ones. Cardiac glycosides act on the Na/K-ATPase (NKA). They show an inverted U-shaped dose-response curve with inhibition of pumping at high concentrations while increasing NKA activity at low concentrations. The classical sigmoidal dose-response curve describing an inhibition of the NKA by cardiac glycosides cannot explain this stimulatory effect. Cardiac glycosides are prototypical examples of hormetic substances. Biphasic dose-response curves of cardiac glycosides are also found in their neurohormonal effects. In low concentrations, vagomimetic effects are observed, whereas in high concentrations, sympathomimetic effects dominate. Lipophilic Digitalis glycosides have greater sympathomimetic effects; hydrophilic Strophanthus glycosides have greater vagomimetic effects. For digoxin, as a strong inotrope, there is evidence of only weak modulation of the autonomic nervous system. In ouabain, the modulation of the autonomic nervous system prevails over weak inotropic effects. Vagomimetic and sympatholytic effects characterize the therapeutic effects. In contrast to those of digoxin, the therapeutic effects of ouabain follow exactly the measurable serum concentration. Contrary to common prejudice ouabain is suitable for oral administration. Timely adjustments of dosage to patient therapeutic needs are easy to achieve with orally administered ouabain. Ouabain has the potential to crucially improve our arsenal of heart failure medications. Therefore, a clinical re-evaluation of ouabain is warranted. Randomized double-blind prospective clinical studies with ouabain, which meet today's standards, are worthwhile and necessary.
[Mh] Termos MeSH primário: Glicosídeos Cardíacos/administração & dosagem
Cardiotônicos/administração & dosagem
Insuficiência Cardíaca/tratamento farmacológico
[Mh] Termos MeSH secundário: Glicosídeos Cardíacos/farmacologia
Cardiotônicos/farmacologia
Glicosídeos Digitálicos/administração & dosagem
Glicosídeos Digitálicos/farmacologia
Digoxina/administração & dosagem
Digoxina/farmacologia
Relação Dose-Resposta a Droga
Desenho de Drogas
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Ouabaína/administração & dosagem
Ouabaína/farmacologia
ATPase Trocadora de Sódio-Potássio/efeitos dos fármacos
ATPase Trocadora de Sódio-Potássio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cardiac Glycosides); 0 (Cardiotonic Agents); 0 (Digitalis Glycosides); 5ACL011P69 (Ouabain); 73K4184T59 (Digoxin); EC 3.6.3.9 (Sodium-Potassium-Exchanging ATPase)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170227
[Lr] Data última revisão:
170227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140927
[St] Status:MEDLINE
[do] DOI:10.1097/MJT.0000000000000151


  8 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26526481
[Au] Autor:de Micheli Serra A; Pastelín Hernández G
[Ad] Endereço:Departamento de Farmacología, Instituto Nacional de Cardiología «Ignacio Chávez¼, México, D.F., México.
[Ti] Título:[A tribute to the memory of the illustrious maestro and academic Dr. Rafael Méndez Martínez, pioneer in the pharmacological studies of digitalis and digitalis glycosides].
[Ti] Título:Breve historia de la digital y los digitálicos. Homenaje a la memoria del ilustre maestro y académico Dr. Rafael Méndez Martínez, pionero de los estudios farmacológicos sobre la digital y los glucósidos digitálicos..
[So] Source:Gac Med Mex;151(5):660-5, 2015 Sep-Oct.
[Is] ISSN:0016-3813
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Since the end of the XVIII century, digitalis glycosides were employed in heart failure. They were considered initially as diuretics and later as cardiotonic agents or as positive inotropics. At the present time there are varied groups of positive inotropic agents, which have a beneficial action on the failing human myocardium. For example, the beta adrenergics, the phosphodiesterase III inhibitors such as milrinone, or the sensibilizers of myocardial proteins to Ca++ such as levosimendan and omecamtiv mecarbil. However, following the opinion of distinguished cardiologists, in the case of heart failure associated to atrial fibrillation, digitalis cannot be substituted.
[Mh] Termos MeSH primário: Glicosídeos Digitálicos/história
Digitalis
Farmacologia/história
[Mh] Termos MeSH secundário: História do Século XVI
História do Século XVIII
História do Século XIX
Seres Humanos
México
[Pt] Tipo de publicação:ENGLISH ABSTRACT; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Digitalis Glycosides)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:151103
[Lr] Data última revisão:
151103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151104
[St] Status:MEDLINE


  9 / 4990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26384484
[Au] Autor:Kim BY; Lee J; Kim NS
[Ad] Endereço:KM-Convergence Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 305-811, Republic of Korea.
[Ti] Título:Helveticoside is a biologically active component of the seed extract of Descurainia sophia and induces reciprocal gene regulation in A549 human lung cancer cells.
[So] Source:BMC Genomics;16:713, 2015 Sep 18.
[Is] ISSN:1471-2164
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although the pharmacological activities of the seed extract of Descurainia sophia have been proven to be useful against cough, asthma, and edema, the biologically active components, particularly at the molecular level, remain elusive. Therefore, we aimed to identify the active component of an ethanol extract of D. sophia seeds (EEDS) by applying a systematic genomic approach. RESULTS: After treatment with EEDS, the dose-dependently expressed genes in A549 cells were used to query the Connectivity map to determine which small molecules could closely mimic EEDS in terms of whole gene expression. Gene ontology and pathway analyses were also performed to identify the functional involvement of the drug responsive genes. In addition, interaction network and enrichment map assays were implemented to measure the functional network structure of the drug-responsive genes. A Connectivity map analysis of differentially expressed genes resulted in the discovery of helveticoside as a candidate drug that induces a similar gene expression pattern to EEDS. We identified the presence of helveticoside in EEDS and determined that helveticoside was responsible for the dose-dependent gene expression induced by EEDS. Gene ontology and pathway analyses revealed that the metabolism and signaling processes in A549 cells were reciprocally regulated by helveticoside and inter-connected as functional modules. Additionally, in an ontological network analysis, diverse cancer type-related genes were found to be associated with the biological functions regulated by helveticoside. CONCLUSIONS: Using bioinformatic analyses, we confirmed that helveticoside is a biologically active component of EEDS that induces reciprocal regulation of metabolism and signaling processes. Our approach may provide novel insights to the herbal research field for identifying biologically active components from extracts.
[Mh] Termos MeSH primário: Brassicaceae/química
Glicosídeos Digitálicos/farmacologia
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Sementes/química
Estrofantinas/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos/farmacologia
Linhagem Celular Tumoral
Biologia Computacional
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Digitalis Glycosides); 0 (Strophanthins); 52OAE3C457 (helveticoside)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150920
[St] Status:MEDLINE
[do] DOI:10.1186/s12864-015-1918-1


  10 / 4990 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26349714
[Au] Autor:Stiefelhagen P
[Ad] Endereço:, .
[Ti] Título:[Digitalis still controversial].
[Ti] Título:Digitalis bleibt umstritten..
[So] Source:MMW Fortschr Med;157(15):30, 2015 Sep 10.
[Is] ISSN:1438-3276
[Cp] País de publicação:Germany
[La] Idioma:ger
[Mh] Termos MeSH primário: Fibrilação Atrial/tratamento farmacológico
Glicosídeos Digitálicos/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
[Mh] Termos MeSH secundário: Glicosídeos Digitálicos/efeitos adversos
Alemanha
Seres Humanos
Metanálise como Assunto
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Digitalis Glycosides)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150909
[Lr] Data última revisão:
150909
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150910
[St] Status:MEDLINE
[do] DOI:10.1007/s15006-015-3463-x



página 1 de 499 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde